IVX-01

IVX-01 is a proprietary, fully canine, high-affinity monoclonal antibody featuring half-life extension technology. Developed by Invetx for veterinary use, it represents a novel biologic designed specifically for dogs. The antibody is engineered to have an extended duration of action in the body, potentially allowing for less frequent dosing compared to conventional antibodies. IVX-01 entered its first clinical field study in dogs in September 2021 and targets an undisclosed chronic indication—likely related to chronic osteoarthritis or pain management based on market research cited by the developer. The drug leverages advanced protein engineering platforms and synthetic antibody discovery technologies through partnerships with companies such as Twist Bioscience[1][2][3][7].